Diabetes Care Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Diabetes Care stocks.

Diabetes Care Stocks Recent News

Date Stock Title
Jul 3 NVO S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
Jul 3 NVO Using Obesity Drugs? Potential Vision Loss Disorder Linked To Novo Nordisk's Ozempic And Wegovy, Study Finds
Jul 3 NVO Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness
Jul 3 NVO Weight-loss drugs linked to rare vision loss: Harvard study
Jul 3 NVO Update: Ozempic, Wegovy Linked to Risk of Blinding Eye Condition, Study Shows
Jul 3 NVO Novo Nordisk’s Ozempic, Wegovy linked to eye disorder in small study
Jul 3 NVO Ozempic Linked to Rare Cases of Vision Loss in Harvard Study
Jul 3 NVO Ozempic, Wegovy Linked to Risk of Blinding Eye Condition, Study Shows
Jul 3 NVO Should You Hold Novo Nordisk A/S (NVO) for the Long Term?
Jul 2 NVO Novo Nordisk and Eli Lilly Slide as Biden Blasts Weight-Loss Drug Prices
Jul 2 NVO Biden, Sanders call for obesity drug makers to cut prices
Jul 2 NVO Fighting words: Lilly and Novo swat back at the Biden/Sanders call for lower GLP-1 prices
Jul 2 NVO Update: Novo Nordisk, Eli Lilly Charging 'Unconscionably' High Prices, Biden, Sanders Say
Jul 2 NVO Top Midday Stories: Tesla, GM Report Vehicle Deliveries; Biden, Sanders Say Novo Nordisk, Eli Lilly Charge 'Unconscionably' High Prices; Warner Bros. Interested in Deal With Paramount
Jul 2 NVO Why Novo Nordisk Stock Is Slipping Today
Jul 2 NVO Novo, Lilly Fall After Biden Slams Duo For 'Unconscionably High' Drug Prices
Jul 2 NVO Eli Lilly history: Beyond the Ticker
Jul 2 NVO Joe Biden Suggests Novo Nordisk, Eli Lilly To Lower Prices For Its Popular Obesity Drugs
Jul 2 NVO Novo, Lilly Slip as Biden Urges Price Cuts on Obesity Drugs
Jul 2 NVO Big Pharma Stocks Sell Off as Biden Calls for Lower Drug Prices
Diabetes Care

Diabetes Care is a monthly peer-reviewed medical journal published since 1978 by the American Diabetes Association. The journal covers research in the following five categories: 1) clinical care/education/nutrition/psychosocial research, 2) epidemiology/health services research, 3) emerging treatments and technologies, 4) pathophysiology/complications, and 5) cardiovascular and metabolic risk. The journal also publishes clinically relevant review articles, letters to the editor, and commentaries.According to the Journal Citation Reports, the journal has a 2017 impact factor of 13.397 ranking it fifth out of 138 journals in the category "Endocrinology & Metabolism."

Browse All Tags